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Cardiopulmonary exercise testing (CPET) is a powerful diagnostic and prognostic tool in the 
management of people with a variety of chronic lung diseases [1–5]. Despite the remarkable increase in 
the number of publications on CPET over the past decades [2], CPET remains underutilised in the field 
of respiratory medicine. Numerous challenges to increase the use of CPET in both clinical practice and 
research await resolution including the establishment of global reference values, in line with those 
available for lung function and pulmonary diffusing capacity [6, 7]. Prior to such an international effort, 
strict standardisation of testing procedures is indispensable to obtaining valid and reliable results and to 
enable interpretation of CPET results within and between centres and individuals. Furthermore, an 
internationally standardised protocol is a prerequisite for the use of CPET data in patient registries and 
in retrospective collaborative research.  
Previous statements by the European Respiratory Society (ERS) [8–10] and the American 
Thoracic Society and the American College of Chest Physicians (ATS/ACCP) [11] partly address 
standardisation, but none of these statements included information on the standardisation of CPET 
procedures with regard to a range of lung diseases, nor considered the patient’s experience of CPET. As 
a consequence, various protocol modifications are used across the world, which may impact the choice 
of reference data and interpretation. The aim of the current document was to provide a strict technical 
standardisation of CPET procedures that could be applied to multiple respiratory conditions.  
A European Respiratory Society (ERS) Task Force of adult and paediatric physicians, 
physiologists, exercise scientists and methodologists with expertise in CPET across a wide range of lung 
diseases conducted a rigorous systematic literature review to provide a comprehensive account of 
published CPET procedures to be uniformly applied across different settings such as research and/or 
clinical practice. Importantly, to gather patients’ perspectives on CPET, we conducted an online survey 




The systematic literature review identified 7914 studies, of which 595 studies with 26,523 patients were 
included in the quantitative analysis [12]. Among included studies, the most common lung diseases 
were chronic obstructive lung disease (COPD) and emphysema (54%), cystic fibrosis (CF, 13%), 
pulmonary arterial hypertension (11%) and lung cancer (7%). Whenever the literature review could not 
inform the Task Force on specific questions, existing guidelines and technical standards were used [8–
11]. 
 
“Cycle ergometry is the preferred testing modality across various lung diseases” 
Cycle ergometry (92% of studies) compared to treadmill ergometry (8% of studies) was the preferred 
testing modality across a wide range of lung diseases (figure 1). Overall, the percentage of studies 
employing 1-minute work rate increments was higher compared to ramp protocols for cycle and 
treadmill exercise testing; see figure 1. While there was a clear preference for minute-by-minute cycle 
ergometer testing protocols in studies with COPD and CF patients, a protocol preference was less clear 
for other lung diseases. Reasons for protocol choices could not be systematically evaluated from the 
majority of original studies.  
 
“Ramp or minute-by-minute protocols are best suited for CPET in chronic lung diseases” 
As already recommended in previous statement and guidelines by the ERS and ATS/ACCP [8, 11], 
incremental exercise protocols with stages of up to 1 minute maximum are best to assess people with 
chronic lung diseases since such protocols not only allow the measurement of peak values but are 
preferred to evaluate important variables during submaximal exercise stages such as the ventilatory 
anaerobic threshold, the slope of the minute ventilation - carbon dioxide output relationship and the 




work rate will be visible in the ventilatory and gas exchange data, thereby reducing the precision of 
determining the above CPET outcomes. 
 
 “Exercise protocol was further standardised” 
In line with previous statements and guidelines, the systematic literature review [12] supports a test 
protocol with a resting phase lasting at least 3 minutes [8–11], a 3-minute “unloaded” phase at the 
lowest work rate provided by the cycle ergometer [8, 9, 11], and an 8- to 12-min incremental phase with 
equal work rate increments every minute [8], followed by a recovery phase of at least 2-3 minutes.  
The Task Force also aimed to establish disease-specific work rate increments using an approach similar 
to that of Wasserman et al. [13]. However, work rate increments have proved difficult to estimate due to 
the lack of reported patient data sets and heterogeneity of lung diseases that clearly limits the use of the 
work rate increment estimations for clinical practice. Previous studies have provided work rate 
increment estimation for cycle ergometry for people with COPD [14], CF [15], asbestosis, silicosis and 
asthma [16] and for treadmill testing for healthy adults [17, 18] and COPD patients [19, 20]. Other, 
more general recommendations for the selection of work rate increments are based on estimated peak 
oxygen uptake (VO2peak) and VO2 during unloaded pedalling [8]. Based on the data available from the 
literature review, some additional guidance is given for the selection of minute-by-minute increments in 
work rate in the full technical standard document [12]. 
 
The rigorous systematic literature review identified a large heterogeneity and substantial lack of 
information with respect to the quality of reporting on CPET equipment, testing protocols and criteria to 




Task Force made suggestions regarding the operational dataset to be reported in future studies in order 
to achieve standardisation of CPET in lung diseases. 
Of studies reporting CPET protocol details for cycle ergometry, only about 42%, 58% and 10% 
provided information on the duration of the resting phase, unloaded phase and recovery phase, 
respectively. For treadmill ergometry, protocol information was given even less often (14%, 39% and 
8%). The selection of workrate increments (e.g. minute-by-minute or continuous) for cycle and treadmill 
exercise testing was rarely reported in the original studies. About 8-10% of all included studies did not 
provide any information on the chosen work rate increment.  
 
Interpretation of CPET results 
In general, the interpretation of CPET results requires the integration of testing results with the patient’s 
medical history, and other clinical findings and investigations. The results of an exercise test may 
prompt further clinical investigations (e.g. vascular assessment, assessment of respiratory or peripheral 
muscle function). In this context, feedback from the patient, including reason for exercise termination, 
can be useful in evaluating exercise limitation. The Task Force report [12] provides a description and 
algorithm of how Task Force members interpret CPET results.  
 
“Patient survey participants perceive exercise testing as beneficial and suggest annual testing as 
optimal“ 
With support by the ELF, the Task Force conducted an online survey available in 34 languages to assess 
patients’ perspectives to gain insights into their perceived relevance and burden of taking part in CPET-
related investigations. Two hundred ninety-five patients from 34 countries responded to the survey. The 
majority were patients with COPD (26%), sarcoidosis (18%), CF (16%) or asthma (13%). Responders 




lung function as the greatest benefit. Many patients perceived the CPET as a highly beneficial part of 
their check-up and provided suggestions that informed this ERS Task Force [12]. For example, 
responders wished to perform CPET in a quieter environment, having the opportunity to sip water or to 
use a fan during the recovery period. In addition, patients highlighted the need for more information 
about the testing procedures and improved individual care during the test. Such information is highly 
relevant and might be incorporated by people conducting and supervising CPETs in their daily work. 
When asked how much of a problem aspects of CPET were, responders rated as “serious problems”: 
dryness in mouth (11%), muscle soreness (10%), bicycle seat discomfort (9%), coughing (9%), and 
mouthpiece discomfort (8%). 
The preferred frequency for participating in CPET reported by nearly 75% of respondents was at least 
yearly (figure 2). 
Future research directions 
The Task Force identified important gaps with respect to CPET protocol standardisation [12]. Future 
research should focus on the standardisation of work rate increments for different lung diseases and the 
collection of large CPET datasets to establish normal values for relevant CPET outcomes in healthy 
subjects across age, including sufficient female and male subjects and a wide range of ethnicities. 
Ideally this should occur in a collaborative effort between the ERS and the Global Lung Function 
Initiative (GLI) [6, 7]. Moreover, future work should address the measurement properties (i.e. test-retest 
reliability and responsiveness to change) of CPET using appropriate analytical methods in patients with 
various lung conditions and across a broad range of disease severity. Finally, this Task Force identified 
a clear lack of studies comparing different CPET procedures (e.g. cycling versus treadmill; different 
duration of warm-up periods; minute-by-minute versus ramp work rate increments; impact of inspiratory 
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Figure 1. Number of publications reporting use of cycle ergometry versus treadmill exercise protocols:  
results from the systematic literature review.   
Figure 2. Reported frequency of participating in cardiopulmonary exercise testing in the future: results 
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